Date | Price Target | Rating | Analyst |
---|---|---|---|
3/16/2023 | $20.00 | Neutral → Buy | BofA Securities |
7/19/2022 | $21.00 → $24.00 | Market Perform → Outperform | Cowen |
10/7/2021 | Overweight → Equal-Weight | Morgan Stanley |
3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus' multimodal real-world datasets and Tempus' biological modeling capabilities to advance Takeda's pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, b
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in Japan for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade Takeda ((TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy. The approval is b
− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality − Data from Long-Term Extension Study will also be Presented − Phase 3 Trial of an Orexin Agonist for Narcolepsy Type 1 Now Enrolling Patients Globally Takeda ((TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain. TAK-861 is an investig
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Lead asset MORF-057 is a small-molecule inhibitor of α4β7 that is currently in Phase 2b trial for ulcerative colitis (UC), with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease (CD). Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst. Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd’s (NYSE:TAK) Entyvio, a mAb tar
Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry. Mos
Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave
2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Revenue Growth of 14.1% at Actual Exchange Rates (AER); +2.1% at Constant Exchange Rate (CER) Driven by Acceleration of Growth & Launch Products (+17.8% at CER) Core Operating Profit Increase of 4.5% at CER Reflecting Phasing of R&D Investment and Other OPEX Reduction; Core Operating Profit Margin of 31.6% for the Quarter No Change to Full Year Forecast or Management Guidance Geographic Expansion with Approvals of LIVTENCITY® in Japan and FRUZAQLA® in EU Late-Stage Pipeline Advances with Positive Phase 2b Data Presented for TAK-861 in Narcolepsy Type 1 and Mezagitamab for Immune Thrombocytopenia (ITP) Takeda ((4502, NYSE:TAK) today announced earnings results for the first qu
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)
BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00
Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously
Morgan Stanley downgraded Takeda Pharmaceutical from Overweight to Equal-Weight